Strain JAU4234, identified as Streptomyces padanus, was isolated from soil collected in Jiangxi Province, China. It produced actinomycin X2, fungichromin, and a new polyene macrolide compound with antifungal activity, antifungalmycin 702. Antifungalmycin 702 had good general antifungal activity and may have potential future agricultural and/or clinical applications.
A ntibiotic discovery for the treatment of pathogen infections is one of the greatest public health achievements of the 20th century. However, pathogenic microbes are rapidly adapting to the antibiotics, making them ineffective and leading to the emergence of resistance (18) . Of particular concern are multiple-drugresistant pathogens such as New Delhi metallo-beta-lactamase 1 (NDM-1)-positive bacteria (6) . Despite this threat and ever increasing public awareness regarding "superbug" infections, treatment options, unfortunately, continue to be limited. One direct course of action to treat drug-resistant pathogenic infections and avoid an epidemic is to discover new antibiotics or to modify the structures of known antibiotics as drug leads.
The Streptomyces genus is a remarkably rich source of natural products, accounting for the production of two-thirds of the commercially available antibiotics (1) . It is noteworthy that this genus still produces a larger number and a wider variety of new antibiotics than the members of any other genus (e.g., meroparamycin, oligomycins, neopeptins, and salaceyin A) and seems to be an almost inexhaustible reservoir of novel antibiotics (2) . In the course of our screening program for new antibiotics, strain JAU4234 was isolated from a soil sample collected at the campus of Jiangxi Agricultural University (Nanchang, Jiangxi province, China), where two new antibiotics, nanchangmycin and meilingmycin, have been discovered in "Streptomyces nanchangensis" NS3226 (14) (15) (16) (Fig. 1) . Strain JAU4234 has the same culture and phenotypic characteristics as S. padanus MITKK-103 (see Fig. S1 in the supplemental material for the morphological characteristics of strain JAU4234 observed by optical and scanning electron microscopy) (7) . Therefore, strain JAU4234 was identified as S. padanus JAU4234. Other strains of this species have been widely used as biocontrol agents in China and Taiwan (12) and are known to produce fungichromin (an antifungal antibiotic) and actinomycin X 2 (an antitumor antibiotic) (7, 12) .
To identify antimicrobially bioactive compounds produced by this strain, 200 liters of fermentation broth was separated into filtrate and mycelium by centrifugation. For the medium and culture conditions used in this work, see the supplemental material. Antimicrobial activity was observed only in the mycelia extract. Figure 2 depicts the separation and purification scheme of bioactive compounds from S. padanus JAU4234. Bioactivity-guided purification resulted in bioactive compounds 1 (800 mg), 2 (350 mg), and 3 (150 mg), obtained from the mycelium. Compound 1 showed strong activity against bacteria but no activity against fungi. Compound 2 and compound 3 exhibited marked antifungal activity but no antibacterial activity.
The chemical structures of compounds 1, 2, and 3 were elucidated (Fig. 3) on the basis of spectroscopic data from fast atom bombardment mass spectrometry (FAB-MS), infrared (IR), UV, 1 H nuclear magnetic resonance (NMR), 13 C NMR, and twodimensional (2D) NMR analyses. The UV spectrum of compound 1 had a typical actinomycin class pattern with an absorption maximum at 444 nm. The spectral patterns of compounds 2 and 3 are characteristic of polyene macrolides (compound 2, max 356, 340, 337, and 320 nm; compound 3, max 318, 303, 290, and 211 nm) (see Fig. S2 in the supplemental material).
High-resolution FAB-MS analysis suggested their molecular masses to be 1,269. 13 C NMR, and distortionless enhancement by polarization transfer spectral data. A search of the SciFinder database (American Chemical Society) showed that seven congeners of actinomycin are known to have a mass of 1,269 Da, elizabethin and fungichromin are the only known polyene antibiotics with a mass of 670, and no known polyene antibiotics have a mass of 704. Therefore, compound 3 could be a new compound.
2D NMR spectrum, including double-quantum filteredcorrelated spectroscopy, heteronuclear multiple-quantum correlation, and heteronuclear multiple bond correlation indicated the presence of proline and 4-oxoproline in compound 1. Only actinomycin X 2 has both proline and 4-oxoproline in the molecule, suggesting that compound 1 is actinomycin X 2 (8, 13) . On the basis of 1D and 2D NMR spectral data, the chemical shift of compound 2 matched that of fungichromin, indicating that compound 2 is likely fungichromin (5, 10, 12) . Compound 3 had a structure similar to that of compound 2, the main distinction being the absence of two olefinic methine carbons and the presence of two oxygen-bearing carbons (one oxygen-bearing methine and one oxygen-bearing quaternary carbon) in compound 3. 2D NMR data suggested that the two hydroxyl groups are located at C-16 and C-25 and that an ester link exists between C-1 and C-27 (see Table S1 in the supplemental material). The putative structure of compound 3 (as elucidated in Fig. S3 in the supplemental material) was compared with all known compounds through a SciFinder database search. The search indicated that compound 3 is a novel polyene macrolide antibiotic we designated antifungalmycin 702.
Spectral data for the novel compound antifungalmycin 702 (compound 3, Fig. 3C Table S1 in the supplemental material.
The in vitro antimicrobial activities of these three compounds were evaluated by determining their MICs (12, 18) . Although compound 1 has been previously isolated and identified, MIC data for the compound are not available. We therefore determined the MICs at which it inhibited 50 and 90% of a selection of Grampositive and Gram-negative bacteria (MIC 50 and MIC 90 , respectively). Compound 1 had strong antibacterial activity against all of the Gram-positive and Gram-negative bacteria examined (Table  1) and was especially effective against S. aureus (MIC 50 , 0.002 g/ml), indicating that compound 1 could have expanded appli- cation as a potential candidate for the treatment of bacterial pathogens such as methicillin-resistant S. aureus and NDM-1-positive bacteria (11) . It should, however, be noted that compound 1 induces greater cytotoxicity in cultured human leukemia cells (HL-60) than actinomycin D, through the stimulation of apoptotic pathways (7). Compound 2, isolated in the 1950s, has been well studied and is widely used as a fungicidal drug for infectious vaginitis (3, 4, 17) . Compound 3 exhibited a broad antifungal activity on 8 plant pathogens at low MICs (Table 2) corresponding to but slightly higher than the MICs of compound 2. In preliminary experiments, compound 3 did not induce acute lethal toxicity at 1,500 mg/kg by the intraperitoneal and oral routes of administration in mice, suggesting low toxicity to mammal cells (data not shown). This is in contrast to the median lethal dose of compound 2, which is only 33.3 mg/kg on intraperitoneal administration to mice (data from SciFinder database). Hence, compound 3 has significant potential as a new antifungal biopesticide or drug lead for applications in the agricultural and medical fields.
Like the fungicidal activities of compound 2 and other polyene macrolide antibiotics, that of compound 3 may involve binding to cell membrane sterols, resulting in an altered cell membrane, leakage of cell constituents, and cell death (9) . The members of the polyene antibiotic family usually possess a macrocyclic lactone ring formed from acetate and propionate by a polyketide pathway (5). The structure shared by compounds 2 and 3 suggests that compound 3 is no exception, likely being derived, as is compound 2, through the condensation of a propionate unit, an octanoate unit, and multiple acetate units, as is typical of polyketide biosynthesis (10) . In summary, because of the encouraging results de- scribed above, our future work will focus on elucidating the antifungal action and biosynthetic pathway of compound 3.
